Prognosis after recovery from ventricular fibrillation complicating ischaemic heart-disease.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005665:Furosemide / Q000627:therapeutic use; D005947:Glucose / Q000627:therapeutic use; D006323:Heart Arrest / Q000150:complications*; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D007511:Ischemia / Q000150:complications*; D008012:Lidocaine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications* / Q000188:drug therapy; D011188:Potassium / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011379:Prognosis; D012151:Resuscitation; D014693:Ventricular Fibrillation / Q000188:drug therapy / Q000209:etiology*
D000900:Anti-Bacterial Agents; D000925:Anticoagulants; D007328:Insulin; D005665:Furosemide; D008012:Lidocaine; D005947:Glucose; D011342:Procainamide; D011188:Potassium